NEW YORK (GenomeWeb News) – Compugen today reported that its third quarter net loss fell 44 percent as the firm cut its R&D and SG&A spending.

The Israeli company reported no revenues for the three-month period ended Sept. 30, compared with revenues of $6,000 for the third quarter of 2008.

Compugen's net loss decreased to $1.9 million, or $.06 per share, from $3.3 million, or $.12 per share, year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.